Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05304520

A Study for Tysabri Participant Preference

Relapsing-Remitting Multiple Sclerosis (RRMS) Clinical Trial

Official title:
SISTER - Subcutaneous: Non-Interventional Study for Tysabri Patient Preference - Experience From Real World

Clinical Trial Summary

The primary objective of this study is to collect, evaluate and compare data on participant preference between subcutaneous (SC) and intravenous (IV) natalizumab. The secondary objectives of this study are to evaluate the immunogenicity of SC natalizumab for natalizumab-naïve participants and collect and evaluate data on the multiple sclerosis (MS) disease-relevant parameters (relapse rate, time to first relapse, disability improvement and progression) over 12 months, in participants with natalizumab therapy starting on SC natalizumab or switching from IV natalizumab.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Multiple Sclerosis
  • Multiple Sclerosis, Relapsing-Remitting
  • Relapsing-Remitting Multiple Sclerosis (RRMS)
Clinical Trial Details
NCT number NCT05304520
Study type Observational
Source Biogen
Contact US Biogen Clinical Trial Center
Phone 866-633-4636
Email clinicaltrials@biogen.com
Status Recruiting
Phase
Start date October 12, 2021
Completion date April 30, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05177523 - Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis
Withdrawn NCT05172466 - Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab N/A
Completed NCT04115488 - Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® Phase 3
Recruiting NCT05811416 - A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
Active, not recruiting NCT03846219 - MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS) Phase 2
Completed NCT02587065 - Plegridy Satisfaction Study in Participants Phase 4
Not yet recruiting NCT02568111 - Brimonidine Tartrate for the Treatment of Injection Related Erythema Phase 4
Terminated NCT01633112 - MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone Phase 3
Completed NCT01738347 - Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS). Phase 1
Terminated NCT02881567 - Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab Phase 3
Not yet recruiting NCT05245344 - Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study